Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
ELTP · OTC · United States · Pharmaceutical Preparations
In shortELITE PHARMACEUTICALS INC /NV/ is profitable.
Financial health
Strong
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 33.0% | 100/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 30.1% | 100/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 58.9% | 100/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | – | n/a |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 6.45× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | – | n/a |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 441.03× | 100/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 7.73 | 100/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 15.3% | 81/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 0.51× | 26/100 |
| Years with positive free cash flow (last 5) | 3 of 5 | 50/100 |
Weight in the score: 20%
| Profitable years (last 5) | 4 of 5 | 80/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 28.8% | 4/100 |
| Operating margin volatility | 8.4% | 33/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 63.3% | 100/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2026 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 32 | 34 | 57 | 84 | 149 |
| Cost of revenue | 17 | 18 | 30 | 44 | 74 |
| Gross profit | 15 | 17 | 26 | 40 | 75 |
| Research & development | 4.1 | 6.2 | 6.9 | 8 | 5.7 |
| Operating income | 5.1 | 3.7 | 11 | 20 | 49 |
| Interest expense | 0.2 | 1.1 | 0.6 | 0.1 | 0.1 |
| Pre-tax income | 6.3 | 4 | 0.5 | (0.1) | 57 |
| Income tax | (1.7) | 0.4 | (20) | 4.3 | 12 |
| Net income | 8.9 | 3.6 | 20 | (4.3) | 45 |
| Diluted EPS | $0.01 | $0.00 | $0.02 | $0.00 | $0.03 |
| Diluted shares (millions) | 1,011 | 1,013 | 1,023 | 1,068 | 1,138 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 8 reported quarters (10-Q and 10-K filings), in USD millions. The fourth quarter is derived from the annual report.
The last 8 quarters of ELITE PHARMACEUTICALS INC /NV/ are included in the Investor plan. Try free for 7 days →
7.73 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
7/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 13, 2026